Olivier J. P. Léger

Most-cited papers

1. A recombinant humanized anti‐insulin‐like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti‐epidermal growth factor receptor therapy against human cancer xenografts

   L. Goetsch, Alexandra Gonzalez, Olivier J. P. Léger, A. Beck +3 more

   2005International Journal of Cancer218 citations Open access

   Semantic Scholar

   Save

2. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy.

   J. Reittie, D. Gottlieb, H. Heslop, Olivier J. P. Léger +5 more

   1989Blood135 citations Open access

   Semantic Scholar

   Save

3. Humanization of a mouse antibody against human alpha-4 integrin: A potential therapeutic for the treatment of multiple sclerosis

   Olivier J. P. Léger, T. Yednock, L. Tanner, H. Horner +6 more

   1997Human Antibodies112 citations

   Semantic Scholar

   Save

4. Bispecific Antibodies: Molecules That Enable Novel Therapeutic Strategies

   N. Fischer, Olivier J. P. Léger

   2007Pathobiology (Basel)75 citations Open access

   Semantic Scholar

   Save

5. Pivotal Involvement of Fcγ Receptor IIA in the Neutralization of Lipopolysaccharide Signaling via a Potent Novel Anti-TLR4 Monoclonal Antibody 15C1*

   I. Dunn-Siegrist, Olivier J. P. Léger, B. Daubeuf, Y. Poitevin +6 more

   2007Journal of Biological Chemistry60 citations Open access

   Semantic Scholar

   Save

6. Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis

   A. Vicari, A. Schoepfer, B. Meresse, L. Goffin +8 more

   2017mAbs43 citations Open access

   Semantic Scholar

   Save

7. Selective Antibody Intervention of Toll-like Receptor 4 Activation through Fc γ Receptor Tethering

   L. Shang, B. Daubeuf, M. Triantafilou, Robin Olden +20 more

   2014Journal of Biological Chemistry37 citations Open access

   Semantic Scholar

   Save

8. The chondroitin sulfate proteoglycan NG2 is a tumour‐specific antigen on the chemically induced rat chondrosarcoma HSN

   Olivier J. P. Léger, C. Johnson-Léger, Elizabeth Jackson, B. Coles +1 more

   1994International Journal of Cancer36 citations

   Semantic Scholar

   Save

9. A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells.

   J. Saldanha, Andrew C. R. Martin, Olivier J. P. Léger

   1999Molecular Immunology24 citations

   Semantic Scholar

   Save

10. Interleukin 2 enhances cytotoxic cell function in vitro after T‐cell depleted marrow transplantation

    Olivier J. P. Léger, H. Drexler, J. Reittie, L. Secker-Walker +2 more

    1987British Journal of Haematology23 citations

    Semantic Scholar

    Save

11. IL‐17F co‐ ;expression improves cell growth characteristics and enhances recombinant protein production during CHO cell line engineering

    Mathias Contie, Olivier J. P. Léger, N. Fouqué, Y. Poitevin +3 more

    2013Biotechnology and Bioengineering7 citations

    Semantic Scholar

    Save

12. Abstract 3220: A novel agonist antibody (INCAGN01876) that targets the costimulatory receptor GITR

    A. Gonzalez, E. Breous, M. Manrique, D. Savitsky +18 more

    20166 citations

    Semantic Scholar

    Save

13. Abstract 3643: INCAGN1876, a unique GITR agonist antibody that facilitates GITR oligomerization

    Ana M. Martín González, M. Manrique, L. Swiech, Thomas Horn +20 more

    20175 citations

    Semantic Scholar

    Save

14. Antibody Engineering

    Kin-Ming Lo, Olivier J. P. Léger, B. Hock

    2014Microbiology spectrum4 citations Open access

    Semantic Scholar

    Save

15. Characterization of syngeneic rat monoclonal antibodies to the HSN tumor using syngeneic monoclonal anti-idiotopic antibodies.

    Olivier J. P. Léger, C. Dean

    1991Journal of Immunology4 citations

    Semantic Scholar

    Save

16. Isolation and characterization of a serologically defined tumour membrane antigen from a chemically‐induced rat sarcoma, HSN

    Olivier J. P. Léger, P. L. Dunn, Brian F. Coles, C. Dean

    1991International Journal of Cancer4 citations

    Semantic Scholar

    Save

17. Primary structure of the variable regions encoding antibody to NG2, a tumour-specific antigen on the rat chondrosarcoma HSN. Correlation of idiotypic specificities with amino acid sequences.

    Olivier J. P. Léger, Elizabeth Jackson, Christopher J. Dean

    1995Molecular Immunology2 citations

    Semantic Scholar

    Save

18. Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

    M. David, Arthur Karaulic, A. Bennetot, Clémence Fournier +9 more

    2026Molecular Oncology0 citations Open access

    Semantic Scholar

    Save

19. A POLYPEPTIDE LINKER FOR PREPARING MULTISPECIFIC ANTIBODIES

    E. Zhukovsky, Olivier J. P. Léger

    20180 citations

    Semantic Scholar

    Save

20. Modified antibody constant region

    Olivier J. P. Léger, P. Rialland, R. Morse

    20170 citations

    Semantic Scholar

    Save

21. Anticorps anti-il-15

    A. Vicari, Olivier J. P. Léger

    20150 citations

    Semantic Scholar

    Save

22. Chemokine receptor antagonist development.

    Alexandre Garin, Z. Johnson, Aurélie Hermant, Fanny Beltran +10 more

    2013Methods in molecular biology0 citations

    Semantic Scholar

    Save

23. Humanization of Antibodies

    Olivier J. P. Léger, J. Saldanha

    20110 citations

    Semantic Scholar

    Save

24. anti-human gamma interferon antibodies and methods of use thereof

    G. Elson, W. Ferlin, N. Fischer, Olivier J. P. Léger

    20060 citations

    Semantic Scholar

    Save

25. Combination therapies against multiple toll-like receptors-and their use

    G. Elson, Olivier J. P. Léger

    20050 citations

    Semantic Scholar

    Save

26. Nouveau recepteur hybride anti-insuline/igf-i ou recepteur hybride anti-insuline/igf-i et anticorps igf-ir et applications

    L. Goetsch, N. Corvaia, A. Duflos, J. Haeuw +2 more

    20040 citations

    Semantic Scholar

    Save

27. Antibodies to igf-ir and their uses

    L. Goetsch, N. Corvaia, Olivier J. P. Léger

    20030 citations

    Semantic Scholar

    Save

28. Antibody with improved production capacity.

    U. Bamberger, P. Garin-Chesa, Olivier J. P. Léger, J. Park +2 more

    19990 citations

    Semantic Scholar

    Save

29. Antibodies with improved productability

    U. Bamberger, P. Garin-Chesa, Olivier J. P. Léger, J. Park +2 more

    19990 citations

    Semantic Scholar

    Save

30. Therapeutic use of humanized antibodies to alpha-4 integrin

    M. Bendig, S. T. Jones, Olivier J. P. Léger, J. Saldanha +6 more

    19960 citations

    Semantic Scholar

    Save

31. Humaniserade antikroppar mot leukocytadhesionsmolekylen VLA-4

    Jose Saldanha, Mary M. Bendig, Olivier J. P. Léger, T. Jones +1 more

    19960 citations

    Semantic Scholar

    Save

32. Humanized Antik|rper against the Leukozytenadh {l} sionsmolek VLA-4

    M. Bendig, Olivier J. P. Léger, J. Saldanha, T. Jones

    19950 citations

    Semantic Scholar

    Save

33. Humanized antibody against the leukocyte vla-4

    M. Bendig, Olivier J. P. Léger, J. Saldanha, T. Jones

    19950 citations

    Semantic Scholar

    Save

34. Isolation and characterization of a monoclonal rheumatoid factor specific for the hinge region of rat IgG2b.

    Olivier J. P. Léger, Christopher J. Dean

    1991Molecular Immunology0 citations

    Semantic Scholar

    Save